An Open-Label Study to Evaluate the Effect on Quality of Life of Switching Kidney Transplant Patients From Reduced Dose EC-MPS to a Higher Than the Equimolar Dose of CellCept.

Trial Profile

An Open-Label Study to Evaluate the Effect on Quality of Life of Switching Kidney Transplant Patients From Reduced Dose EC-MPS to a Higher Than the Equimolar Dose of CellCept.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 21 Jul 2011

At a glance

  • Drugs Mycophenolate mofetil; Mycophenolate sodium
  • Indications Renal transplant rejection
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 19 Nov 2007 Status changed from recruiting to discontinued.
    • 20 Jan 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top